Han, Jang Lee, Sungyup Lee, Byounghwa Baek, Ock-Kee Herlemann, Annika Lonergan, Peter Jeong, Chang Cooperberg, Matthew Carroll, Peter Washington, Samuel
...
Although there are several decision aids for the treatment of localized prostate cancer (PCa), there are limitations in the consistency and certainty of the information provided. We aimed to better understand the treatment decision process and develop a decision-predicting model considering oncologic, demographic, socioeconomic, and geographic fact...
Englman, Cameron Barrett, Tristan Moore, Caroline M Giganti, Francesco
Multiparametric magnetic resonance (MR) imaging has had an expanding role in active surveillance (AS) for prostate cancer. It can improve the accuracy of prostate biopsies, assist in patient selection, and help monitor cancer progression. The PRECISE recommendations standardize reporting of serial MR imaging scans during AS. We summarize the eviden...
Beckmann, Kerri Santaolalla, Aida Sugimoto, Mikio Carroll, Peter Rubio, Jose Villers, Arnauld Bjartell, Anders Morgan, Todd Dasgupta, Prokar Van Hemelrijck, Mieke
...
BackgroundCurrently, follow-up protocols are applied equally to men on active surveillance (AS) for prostate cancer (PCa) regardless of findings at their initial follow-up biopsy. To determine whether less intensive follow-up is suitable following negative biopsy findings, we assessed the risk of converting to active treatment, any subsequent upgra...
Kuhlmann, Paige K Oyekunle, Taofik Klaassen, Zachary Amling, Christopher L Aronson, William J Cooperberg, Matthew R Kane, Christopher J Terris, Martha K Freedland, Stephen J
PurposeLimited data exist to help surgeons decide between active surveillance (AS) versus treatment for men with favorable intermediate risk (FIR) prostate cancer. To estimate the theoretical excess risk of prostate cancer-specific mortality (PCSM) with AS versus radical prostatectomy (RP), we determined the risk of PCSM in FIR men undergoing RP an...
Glencer, Alexa C Miller, Phoebe N Greenwood, Heather Rodas, Cristian K Maldonado Freimanis, Rita Basu, Amrita Mukhtar, Rita A Brabham, Case Kim, Paul Hwang, E Shelley
...
Ductal carcinoma in situ (DCIS) is a biologically heterogenous entity with uncertain risk for invasive ductal carcinoma (IDC) development. Standard treatment is surgical resection often followed by radiation. New approaches are needed to reduce overtreatment. This was an observational study that enrolled patients with DCIS who chose not to pursue s...
Parsons, J Kellogg Zahrieh, David Patel, Devin Mohler, James L Chen, Ronald C Paskett, Electra D Liu, Heshan Peil, Elizabeth S Rock, Cheryl L Hahn, Olwen
...
BackgroundHealth-related quality of life (HRQoL) among patients with localized prostate cancer (PC) on active surveillance (AS) and whether it may be improved through lifestyle-focused interventions remain underdefined.ObjectiveTo assess longitudinal changes in HRQoL in patients who received and those who did not receive a behavioral intervention t...
Brady, Lauren Newcomb, Lisa F Zhu, Kehao Zheng, Yingye Boyer, Hilary De Sarkar, Navonil McKenney, Jesse K Brooks, James D Carroll, Peter R Dash, Atreya
...
BackgroundPathogenic germline mutations in several rare penetrant cancer predisposition genes are associated with an increased risk of aggressive prostate cancer (PC). Our objectives were to determine the prevalence of pathogenic germline mutations in men with low-risk PC on active surveillance, and assess whether pathogenic germline mutations asso...
Filson, Christopher Zhu, Kehao Huang, Yijian Zheng, Yingye Newcomb, Lisa Williams, Sierra Brooks, James Dash, Atreya Ellis, William Gleave, Martin
...
PURPOSE: We assessed whether Prostate Health Index results improve prediction of grade reclassification for men on active surveillance. METHODS AND MATERIALS: We identified men in Canary Prostate Active Surveillance Study with Grade Group 1 cancer. Outcome was grade reclassification to Grade Group 2+ cancer. We considered decision rules to maximize...
Sushentsev, Nikita Rundo, Leonardo Abrego, Luis Li, Zonglun Nazarenko, Tatiana Warren, Anne Y Gnanapragasam, Vincent J Sala, Evis Zaikin, Alexey Barrett, Tristan
...
Serial MRI is an essential assessment tool in prostate cancer (PCa) patients enrolled on active surveillance (AS). However, it has only moderate sensitivity for predicting histopathological tumour progression at follow-up, which is in part due to the subjective nature of its clinical reporting and variation among centres and readers. In this study,...
Sushentsev, Nikita Barrett, Tristan
In a Review published in Nature Reviews Urology, Ploussard and colleagues discuss the evolving role of magnetic resonance imaging (MRI) in guiding active surveillance (AS) for patients with prostate cancer (Ploussard, G., Rouvière, O., Rouprêt, M., van den Bergh, R. & Renard-Penna, R. The current role of MRI for guiding active surveillance in prost...